share_log

Panbela Therapeutics | 10-Q: Q2 2024 Earnings Report

Panbela Therapeutics | 10-Q: Q2 2024 Earnings Report

Panbela Therapeutics | 10-Q：2024财年二季报
美股SEC公告 ·  08/14 05:13

Moomoo AI 已提取核心信息

Panbela Therapeutics, Inc. reported its financial performance for the quarter ended June 30, 2024, revealing a net loss of $7.1 million, an increase from the $5.8 million loss in the same period the previous year. The company's operating expenses rose to $8.1 million, up from $5.9 million, primarily due to increased research and development costs associated with the ASPIRE trial for its lead product candidate, ivospemin. Despite a gain on the sale of intellectual property and other income, the company's financial position remains challenged, with a working capital deficit of $16 million and cash reserves of only $59,000. Panbela's business development has been focused on advancing ivospemin, with ongoing clinical trials and regulatory efforts. The company's future plans include seeking additional financing to support operations and continue the development of ivospemin and other product candidates. However, the company faces significant risks, including the need for additional capital, the success of clinical trials, and obtaining regulatory approvals.
Panbela Therapeutics, Inc. reported its financial performance for the quarter ended June 30, 2024, revealing a net loss of $7.1 million, an increase from the $5.8 million loss in the same period the previous year. The company's operating expenses rose to $8.1 million, up from $5.9 million, primarily due to increased research and development costs associated with the ASPIRE trial for its lead product candidate, ivospemin. Despite a gain on the sale of intellectual property and other income, the company's financial position remains challenged, with a working capital deficit of $16 million and cash reserves of only $59,000. Panbela's business development has been focused on advancing ivospemin, with ongoing clinical trials and regulatory efforts. The company's future plans include seeking additional financing to support operations and continue the development of ivospemin and other product candidates. However, the company faces significant risks, including the need for additional capital, the success of clinical trials, and obtaining regulatory approvals.
Panbela Therapeutics, Inc.公布了截至2024年6月30日的财务业绩，净亏损为710万美元，相比上年同期的580万美元亏损有所增长。该公司的营业费用上升至810万美元，上年同期为590万美元，主要是由于其首席产品候选药物ivospemin的ASPIRE试验关联的研发费用增加。尽管从知识产权出售和其他收入中获得了收益，该公司的财务状况仍然具有挑战性，工作资本赤字达1600万美元，现金储备仅为59000美元。Panbela的业务发展重点是推动ivospemin，继续进行临床试验和监管工作。该公司未来计划包括寻求额外融资以支持运营并继续开发ivospemin和其他产品候选物。但是，该公司面临着重大风险，包括需额外资本、对临床试验的成功以及获得监管批准等。
Panbela Therapeutics, Inc.公布了截至2024年6月30日的财务业绩，净亏损为710万美元，相比上年同期的580万美元亏损有所增长。该公司的营业费用上升至810万美元，上年同期为590万美元，主要是由于其首席产品候选药物ivospemin的ASPIRE试验关联的研发费用增加。尽管从知识产权出售和其他收入中获得了收益，该公司的财务状况仍然具有挑战性，工作资本赤字达1600万美元，现金储备仅为59000美元。Panbela的业务发展重点是推动ivospemin，继续进行临床试验和监管工作。该公司未来计划包括寻求额外融资以支持运营并继续开发ivospemin和其他产品候选物。但是，该公司面临着重大风险，包括需额外资本、对临床试验的成功以及获得监管批准等。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间